2015-07-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/647366摘要：台灣阻塞性肺病臨床試驗合作聯盟(Taiwan Clinical Trial Consortium for Obstructive Airway Diseases, TCoC)主要專注於不只是阻塞型呼吸道疾病(例如慢性阻塞型肺病、氣 喘、睡眠呼吸中止等)還有其他肺部疾病(例如特發性肺纖維化、肺結核、肺炎等），上述 阻塞型呼吸道疾病和其他肺部疾病對人類仍是威脅，仍需要更多的研究來幫助病人。以 慢性阻塞性肺疾病為例，慢性阻塞性肺疾病是一個重大的公共衛生問題，主要是由吸煙 所引起的。2004年，慢性阻塞性肺病導致每年275萬例死亡，佔全世界首要死亡原因 第四位。在過去的幾十年，儘管吸煙率下降，慢性阻塞性肺病所造成的死亡仍是大幅上 升。慢性阻塞性肺病無法治癒，治療只能緩解症狀。預防和開發新方法來治療慢性阻塞 是迫切需要的。儘管慢性阻塞性肺病是一種常見的疾病，而且也消耗大量的醫療開支 (2005年約2400萬新台幣），但是前瞻性的全國性的流行病學研究或臨床試驗是缺乏 的。TCoC是由多位胸腔醫學、肺部影像和資料分析的專家所組成，他們有豐富的基礎實驗 和臨床研究經驗。TCoC重要任務將是協助設計和進行多中心（研究者或國際研究組織 與藥廠發起的）臨床試驗，以及建立阻塞型呼吸道疾病和其他肺部疾病患者的資料庫。 中心辦公室將提供通訊聯絡，資料庫維護和核心研究的協調窗口。TCoC核心設施也會 將提供臨床研究者進行候選基因的SNP分析。參與者需要簽署知情同意書來提供臨床 資訊，血液/血漿/血清/灌洗液存儲和基因SNP分析。台灣慢性阻塞性肺病聯盟有能力每 年招收大約700-800慢性阻塞性肺病患者（從每家醫院大約每年80例）。病人的臨床資 料會使用網路建置的系統加以收集供日後分析使用。TCoC最終的目標是推動針對肺部 疾病有治療潛力的臨床試驗，並加速治療方法發展的速度，使患者的壽命得以延長，生 活品質獲得改善。<br> Abstract: Taiwan Clinical Trial Consortium for Obstructive Airway Diseases (TCoC) mainly focuses in not only obstructive airway diseases (such as chronic obstructive pulmonary disease (COPD), asthma, and obstructive sleep apnea), but also other pulmonary diseases (such as idiopathic pulmonary fibrosis (IPF), pulmonary tuberculosis, and pneumonia). The obstructive airway and pulmonary diseases mentioned above still problems to human beings and need further studies to help patients. Taking COPD for example, COPD is a major public health problem mainly caused by cigarette smoking. In 2004, COPD causes 2.75 million deaths annually, representing the fourth leading cause of death worldwide. Mortality due to COPD has risen sharply over the past several decades despite a major decline in smoking prevalence. There is no cure for COPD, and treatments are only moderately effective at relieving symptoms. Novel approaches for prevention and treatment of COPD are urgently needed. Although COPD is a common disease in our population and consumes a large amount of health care expenditure (about 2400 million NTD in 2005), studies regarding longitudinal, prospective nationwide epidemiology, or intervention are lacking.TCoC is a collaborative consortium by specialists of database processing, chest image and pulmonary medicine. They are full of experience in basic research and clinical practice The key missions of the TCoC will be to assist the design and conduct of multi-center (investigator-initiated, industry or international research groups) clinical trials, as well as the establishment of biospecimen database of obstructive airway and other pulmonary diseases patients. Central office will provide the window of communication, database maintenance and core study coordination. The core facility of TCoC will provide candidate genes SNP analysis under a collaborative clinical research. Participating subjects need to sign the informed consent for clinical data , PBMC/plasma/serum/ lavage fluids storage and gene SNP analysis. By estimation, the consortium has the ability to enroll 700-800 patients per year (80 patients from each site per year). Core clinical information will be collected using a web based information system for future analysis. The ultimate goal for TCoC is to enable clinical trials of potential therapies for lung diseases and speed the development of treatments that will improve the length and quality of life for patients.